Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 1/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | MMP14 | P50281 | 4/20 | 0.34 |
| ▸ | MMP8 | P22894 | 3/20 | 0.34 |
| ▸ | MMP17 | Q9ULZ9 | 3/20 | 0.34 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | MMP13 | P45452 | 2/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13363340 | 0.81 | ADAM17 (0.41) | ADAM17MMP14MMP8MMP17MMP2 | |
| SCHEMBL10200839 | 0.81 | ADAM17 (0.41) | ADAM17MMP14MMP8MMP17MMP2 | |
| SCHEMBL3412312 | 0.79 | ADAM17 (0.44) | ADAM17MMP2MMP3CNR1 | |
| SCHEMBL10112557 | 0.75 | ADAM17 (0.41) | TNFADAM17MMP14MMP8MMP17 | |
| SCHEMBL7900340 | 0.75 | ADAM17 (0.41) | TNFADAM17MMP14MMP8MMP17 | |
| SCHEMBL14978283 | 0.73 | NPC1 (0.39) | ADAM17MMP14MMP2MMP13MMP3 | |
| SCHEMBL12378820 | 0.68 | ADAM17 (0.51) | ADAM17MMP8MMP2MMP13MMP3 | |
| SCHEMBL6135313 | 0.66 | LMNA (0.51) | ADAM17AKR1B1MMP2MMP13ADAMTS5 | |
| SCHEMBL4385865 | 0.66 | LMNA (0.51) | ADAM17AKR1B1MMP2MMP13ADAMTS5 | |
| SCHEMBL204119 | 0.66 | LMNA (0.51) | ADAM17AKR1B1MMP2MMP13ADAMTS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541572-B2 | Compounds for the treatment of inflammatory disorders | MERCK SHARP & DOHME CORP. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541572-B2 | Compounds for the treatment of inflammatory disorders | MERCK SHARP & DOHME CORP. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120010181-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | MERCK SHARP & DOHME CORP. | 2012-01-12 | — | — | US | disclosed |
| US-20120010181-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | MERCK SHARP & DOHME CORP. | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010181-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, ADAMTS1, ADAMTS7 | TNF 1/4885ADAM17 7/4885AKR1B1 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.